Get the Stockscreener App
143.98
5.87%
7.98
Pre-market:
145.29
1.31
+0.91%
Insmed Inc stock is traded at $143.98, with a volume of 4.06M.
It is up +5.87% in the last 24 hours and down -9.46% over the past month.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
See More
Previous Close:
$136.00
Open:
$147.12
24h Volume:
4.06M
Relative Volume:
1.42
Market Cap:
$31.04B
Revenue:
$606.42M
Net Income/Loss:
$-1.28B
P/E Ratio:
-22.49
EPS:
-6.403
Net Cash Flow:
$-997.58M
1W Performance:
-0.43%
1M Performance:
-9.46%
6M Performance:
-0.96%
1Y Performance:
+80.16%
1-Day Range:
$141.64
$149.76
1-Week Range:
$135.73
$149.76
52-Week Range:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
143.98 | 31.04B | 606.42M | -1.28B | -997.58M | -6.403 |
VRTX
Vertex Pharmaceuticals Inc
|
451.24 | 114.63B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
736.53 | 77.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
681.85 | 42.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
306.66 | 40.67B | 3.71B | 313.75M | 465.38M | 2.2571 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Insmed reports positive Phase 3b trial results for MAC lung disease drug - Investing.com Australia
A Look At Insmed (INSM) Valuation After Positive ENCORE Phase 3b ARIKAYCE Data - Yahoo Finance
Analyst weighs patent cliff risks against Insmed’s (INSM) growth story - MSN
Insmed CEO on its Arikayce drug after shares surge on trial results - MSN
Insmed Shares Climb on Positive Results for Arikayce - marketscreener.com
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
Market movers: Palantir Technologies, Insmed, Synopsys… - Proactive financial news
Insmed Announces Positive Phase 3b ENCORE Results for ARIKAYCE in MAC Lung Disease, Plans FDA Supplemental NDA Filing in 2026 - Minichart
BofA raises Insmed stock price target on positive trial data By Investing.com - Investing.com Canada
Insmed (INSM) Achieves Milestone with Positive Phase 3 ENCORE Tr - GuruFocus
Insmed Lung Infection Therapy Data Impresses, Analyst Sees Approval Path - Benzinga
Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains - Yahoo Finance
Insmed (INSM): ENCORE Phase 3 Success Expands MAC Lung Disease Opportunity and Underscores Arikayce Upside - TipRanks
Jefferies raises Insmed stock price target on positive trial data By Investing.com - Investing.com Canada
Insmed’s Arikayce data tees up sNDA filing in MAC lung disease - The Pharma Letter
Pulmonary Arterial Hypertension Market: Expanding Revenue Landscape to 2034 – DelveInsight | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros Therapeutics - Barchart
Insmed shares rise as Arikayce trial data point to larger market opportunity - Investing.com Canada
Insmed (NASDAQ:INSM) Shares Gap UpWhat's Next? - MarketBeat
Wolfe Research reiterates Insmed stock rating on Brinsupri momentum By Investing.com - Investing.com Canada
FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares - BioPharma Dive
Insmed shares rise on positive late-stage trial results for lung disease therapy - Proactive Investors
Insmed (INSM) Shares Surge Following Positive Phase 3b Study Res - GuruFocus
Stifel reiterates Insmed stock rating on positive trial data By Investing.com - Investing.com Canada
Insmed stock jumps on positive drug trial results By Investing.com - Investing.com Canada
Insmed reveals promising Phase 3b trial data for untreated MAC lung infection patients - Traders Union
Insmed (INSM) Achieves Positive Results in Phase 3b Study for AR - GuruFocus
Insmed Reports Positive Phase 3b ENCORE ARIKAYCE Results - TipRanks
S&P 500 Futures Rise in Premarket Trading; Insmed, Mobileye Global Lead - Barron's
Insmed drug benefits patients with rare, bacterial lung disease, study shows - statnews.com
ENCORE success positions Insmed (Nasdaq: INSM) to seek ARIKAYCE label expansion - Stock Titan
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease - Yahoo Finance
Insmed Incorporated(NasdaqGS: INSM) added to FTSE All-World Index - marketscreener.com
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story - The Motley Fool
How Insmed (INSM) Is Rewriting Its Story Around Brinsupri And 2026 Expectations - Yahoo Finance
Insmed chair and CEO Lewis sells $1.5M in shares By Investing.com - Investing.com Canada
Insmed (INSM) poised for 2026 upside with potential $1.3B Arikayce sales boost, Roth/MKM initiates buy - MSN
Form 144 INSMED INC For: 5 March By Investing.com - Investing.com Australia
Insmed chair and CEO Lewis sells $1.5M in shares - Investing.com
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 10,699 Shares of Stock - MarketBeat
INSMED (NASDAQ: INSM) CEO exercises options and sells 10,699 shares under 10b5-1 plan - Stock Titan
Brensocatib Approval Gives Insmed New Growth Pillar And Valuation Gap - Yahoo Finance
Cystic Fibrosis Market: Rapid Growth & Investment Outlook to 2034 – DelveInsight | Insmed, AstraZeneca, Zambion, The Marcus Foundation, Chiesi Farmaceutici, SolAeroMed - Barchart
INSM Stock Price, Quote & Chart | INSMED INC (NASDAQ:INSM) - ChartMill
William Lewis reports share sales at INSM (NASDAQ: INSM) in Form 144 - Stock Titan
Artisan Small Cap Fund Sold Insmed (INSM) on Valuation Consideration - Yahoo Finance
Novo Holdings A S Sells 480,000 Shares of Insmed, Inc. $INSM - MarketBeat
Long Focus Capital Management LLC Sells 182,200 Shares of Insmed, Inc. $INSM - MarketBeat
Millennium Management LLC Has $336.42 Million Stake in Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. $INSM Stock Position Decreased by Jain Global LLC - MarketBeat
Fred Alger Management LLC Has $13.54 Million Holdings in Insmed, Inc. $INSM - MarketBeat
Granahan Investment Management LLC Reduces Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insmed Inc Stock (INSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Mar 19 '26 |
Sale |
143.52 |
10,699 |
1,535,542 |
301,185 |
0.20%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):